

Recombinant human NMP-22 protein, His

Catalog Number: bs-41336P

Concentration: >0.5 mg/ml

AA Seq: 2-410/2115

Predicted MW: 47

Detected MW: 52 kDa

Tags: His

Activity: Not tested

Endotoxin: Not analyzed

Purity: >90% as determined by SDS-PAGE

Purification: AC

Form: Lyophilized or Liquid

Storage: 20mM Tris-HCl (pH8.0).

Stored at -70°C or -20°C. Avoid repeated freeze/thaw cycles.

Background: Healthy individuals generally have very small amounts of NMP22 protein in the urine. However, the level of NMP22 protein is often elevated in the urine of patients with bladder cancer, even at early stages of the disease.¹ The Alere NMP22 Test is an enzyme immunoassay for the quantitative determination of nuclear mitotic apparatus protein (NuMA) in stabilized voided urine. NuMA is an abundant component of the nuclear matrix proteins (NMP22). The Alere NMP22?BladderChek?Test is the only in-office test approved by the FDA as an aid in the diagnosis and monitoring of bladder cancer in conjunction with standard diagnostic procedures. Both assays are painless and non-invasive and detect elevated levels of NMP22 protein.

VALIDATION IMAGES



The purity of the protein is greater than 90% as determined by reducing SDS-PAGE.